Welcome to our dedicated page for Cellebrite DI Ltd. SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold ordinary shares in a scheduled transaction. On August 24, 2026, he sold 4,323 shares of ordinary shares at a weighted average price of $11.3605 per share, with individual trade prices ranging from $11.06 to $11.76. The sale was effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, and Gee now directly holds 135,281 shares of Cellebrite stock.
Cellebrite DI Ltd. (CLBT) is the issuer of common stock that David Gee, identified as an officer, plans to sell under Rule 144. The notice covers a proposed sale of 4,323 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate market value of $47,769.15 as of August 24, 2026. The securities to be sold arise from Restricted Stock Units from the issuer. The filing also lists prior sales by David Gee over the past three months.
Cellebrite DI Ltd. (CLBT) reported that Global Chief Revenue Officer Marcus Jewell sold 12,562 ordinary shares on August 21, 2026. The transaction was executed at a weighted average price of $11.2416 per share, from multiple trades between $11.16 and $11.30. According to the disclosure, these shares were originally granted as restricted stock units on November 15, 2023, and the disposition is associated with Jewell’s tax obligations related to RSU vesting. Following the sale, he directly holds 427,128 ordinary shares of Cellebrite.
Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold 2,198 ordinary shares on August 21, 2026 in an open-market transaction at a weighted average price of $11.2416 per share, with individual trades ranging from $11.16 to $11.30. The shares sold were originally granted as restricted stock units (RSUs) on May 20, 2024, and the disposition is associated with the reporting person’s tax obligations upon vesting of those RSUs. Following this transaction, Gee directly holds 139,604 ordinary shares of Cellebrite DI Ltd.
Cellebrite DI Ltd. (CLBT) is the issuer for which Thomas E. Hogan has filed a Rule 144 notice covering ordinary shares, par value NIS 0.00001 per share, listed on Nasdaq. The shares relate to restricted share units vested under an issuer S-8 registered compensation plan.
The reporting person states an intention to sell shares on 08/25/2026 through Morgan Stanley Smith Barney LLC under a mandatory, non-discretionary sell-to-cover arrangement solely to satisfy income tax liabilities from RSU vesting. Recent activity includes open-market sales of Cellebrite ordinary shares during the past three months.
Cellebrite DI Ltd. (CLBT) was notified that officer David Nicholas Gee filed to sell 5,673 ordinary shares of the company under Rule 144. The shares relate to restricted share units vesting under an S-8 registered compensation plan, and the filing states the sale on 08/21/2026 will be a mandatory, non-discretionary sell-to-cover transaction to satisfy income tax liabilities from vesting of performance share unit awards only. The notice also lists prior small Rule 144 sales over the past three months.
Cellebrite DI Ltd. (CLBT) received a notice that officer Marcus Jewell intends to sell ordinary shares under Rule 144. The notice covers 31,728 ordinary shares, with an indicated value of $331,240.32, to be sold on 08/21/2026. The shares relate to restricted share units vested under an issuer S-8 registered compensation plan, and the sale is described as a mandatory, non-discretionary sell-to-cover arrangement to satisfy income tax liabilities from vesting of performance share unit awards. The filing also lists smaller sales in the prior three months.
Cellebrite DI Ltd. (CLBT) has a new significant shareholder group led by Voss Capital and related entities, disclosed as passive owners on a Schedule 13G. Voss Value Master Fund, L.P. reports beneficial ownership of 1,750,000 ordinary shares, and Voss Value‑Oriented Special Situations Fund, L.P. reports 300,000 shares.
Voss Advisors GP, LLC, as general partner of the two funds, may be deemed to beneficially own a total of 2,050,000 shares. Voss Capital, L.P., as investment manager to the funds and certain managed accounts, may be deemed to beneficially own 12,700,000 shares, representing about 5.1% of Cellebrite’s 250,785,933 shares outstanding as of June 30, 2026, with approximately 10,650,000 of these held in managed accounts. Travis W. Cocke, as managing member of Voss Capital and Voss GP, may likewise be deemed to beneficially own 12,700,000 shares (about 5.1% of the class).
Cellebrite DI Ltd. (CLBT) called its 2026 Annual General Meeting for September 24, 2026 in Israel and furnished a detailed proxy statement with four voting items: re-electing two Class II directors until 2029, approving CEO Shiven Ramji’s compensation package, approving an updated compensation policy for officers and directors, and re-appointing Kost Forer Gabbay & Kasierer (EY Israel) as independent auditor for 2026 with Board-set fees.
New CEO Shiven Ramji reported that Cellebrite delivered record 2025 financial results, including 21% Annual Recurring Revenue growth and an approximately 34% free cash flow margin, producing “Rule of 55” performance above the company’s stated 45–50 target range. He highlighted acquisitions of Corellium and SCG and new AI-driven products Guardian Investigate and Genesis to expand from digital forensics into a broader investigation intelligence platform.
Ramji also disclosed that second-quarter 2026 ARR fell short of expectations, leading Cellebrite to lower its full-year ARR and revenue outlook while raising its adjusted EBITDA target. The company attributes softer ARR to longer sales cycles, added public-sector procurement complexity and weaker-than-expected expansion from Inseyets conversions, and is responding with sharpened sales execution, tighter resource focus and continued product investment. Shareholders are asked to approve a largely equity-based CEO package (base salary $500,000, 100% target bonus and sizable RSU/PSU grants) and a refreshed, more prescriptive compensation policy that tightens bonus caps, strengthens clawbacks and limits termination and change-of-control benefits.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported equity compensation and related share withholding. On August 11, 2026, 339,484 ordinary shares were delivered to him upon certification that performance conditions for awards granted on September 19, 2025 were met. On August 12, 2026, 139,713 shares from this vesting were withheld and disposed of to cover his tax obligations at a weighted average price of $15.3861 per share, with individual trades between $15.06 and $15.73. The transactions are reported as directly owned and are not affirmed as executed under a Rule 10b5-1 trading plan.